Bgm (BGM) Net Income towards Common Stockholders (2024 - 2025)
Bgm (BGM) posted quarterly Net Income towards Common Stockholders of $182.1 million for Q1 2025, up 326.08% quarter-over-quarter from $42.7 million in Q3 2024.
Bgm (BGM) Net Income towards Common Stockholders (2024 - 2025) Analysis & Trends
Bgm (BGM) has reported Net Income towards Common Stockholders for 2 consecutive years, with $182.1 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Net Income towards Common Stockholders changed N/A year-over-year to $182.1 million; the TTM figure through Sep 2025 stood at $224.9 million (up 426.08% YoY), while the FY2025 annual figure was -$19.9 million, down 1282.09% from the prior year.
- Net Income towards Common Stockholders improved to $182.1 million in Q1 2025 per BGM's latest filing, from $42.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $182.1 million in Q1 2025 and bottomed at $42.7 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Bgm | 29.92 Mn | 20.10 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 182.12 Mn |
| Sep 30, 2024 | 42.74 Mn |